The study for usefulness of switching nucleoside/nucleotide analogues (NAs) to tenofovir alafenamide fumarate in patients with chronic HBV infection treated with other NAs
Not Applicable
- Conditions
- chronic HBV infection
- Registration Number
- JPRN-UMIN000030661
- Lead Sponsor
- Saitama Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 70
Inclusion Criteria
Not provided
Exclusion Criteria
(1) Patients who is taking immunosuppressive agents (2) Patients who is infected also with HIV (3) Patients treated with contraindicated drug together with TAF. (4) Patients who is considered inappropriate for this study by doctors in attendance
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method HBs antigen level and frequency of occurrence of adverse events (including abnormal clinical laboratory tests) at 5 years after the initiation of TAF administration.
- Secondary Outcome Measures
Name Time Method